Exclusive Summary

• Highly targeted essential niche market: As a classic vasodilator compound, it addresses irreplaceable clinical needs in treating resistant hypertension and pregnancy-induced hypertension.
• Strong cost-effective supply chain: Leveraging China's robust API-to-FDF integrated manufacturing, it offers highly cost-effective finished drugs perfect for public tenders in emerging markets.
• Better compliance via compound formulation: It provides synergistic blood pressure reduction while minimizing side effects of monotherapy, serving as an optimal basic treatment option.
• Zero IP barriers for rapid entry: With original patents long expired, there is no infringement risk, allowing for rapid commercialization and local market penetration through the Distribution model.